Stocks
The weight loss wars get heavier
One says pill, one says combo drug.
Follow pharma stocks, biotech, medical devices, clinical trials, and healthcare policy developments moving health sector equities.
One says pill, one says combo drug.
That's more bad news for Novo Nordisk.
Will it be enough to turn things around?
Shares exploded over 140% higher.
And CVS wants in on the weight-loss action.
But Wall Street isn't convinced it will work.
Stay up to date on the latest market news with daily analysis of the investing landscape, served up Brew-style.
By subscribing, you accept our Terms & Privacy Policy.